Claim Missing Document
Check
Articles

Found 2 Documents
Search

Diabetes Caused by Statin Use: A Review Zulfiana, Risa; Medina, Farah; Suharjono, Suharjono
Journal of Islamic Pharmacy Vol 5, No 1 (2020): J. Islamic Pharm.
Publisher : Universitas Islam Negeri Maulana Malik Ibrahim Malang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18860/jip.v5i1.8652

Abstract

Statins are generally recognised as being safe and well tolerated cholesterol-lowering drug and have been successfully used for prevention of primary and secondary cardiovascular disease. However, Some researchers have reported diabetes development in patients taking statins. A number of meta-analyses conducted in recent years have proved that the association is real even though its causality have not been fully elucidated. Various pathophysiological mechanisms that could explain the increased risk of diabetes in patients treated with statin have been described. These are mainly responsible for impairment of β -cell insulin secretion and alteration of intercellular signaling through depletion of important downstream products.  This review aims to examine the relationship between statin treatment and the presence of diabetes. Previous clinical reviews of the evidence and pathophysiological mechanisms involved may also be explained. Furthermore, many studies have concluded that Pitavastatin and pravastatinom do not affect glycemic control and may be a beneficial treatment option in patients with, or at risk for, type 2 diabetes.
Evaluating fondaparinux vs bovine-derived enoxaparin as halal anticoagulants in East Java Provincial Haji Hospital Samlan, Karima; Ayumuyas, Nur Palestin; Ramdani, Dewi; Zulfiana, Risa; Sari, Annisa Kartika; Isnaeni, Isnaeni
Journal of Halal Science and Research Vol. 6 No. 2 (2025): September
Publisher : Universitas Ahmad Dahlan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.12928/jhsr.v6i2.12277

Abstract

This study evaluated the effectiveness of two halal anti-coagulant therapies used in patients at East Java Provincial Haji Hospital. The research design was a retrospective, comparative, observational study spanning the last three years. The study population consisted of patients assigned to anti-coagulant therapy, divided into two groups based on the use of two halal anti-coagulants: bovine enoxaparin and fondaparinux. Participation in this study is voluntary, and all patient data will be kept confidential in accordance with data protection laws. Inclusion criteria were patients with diagnoses requiring anticoagulants, such as atrial fibrillation, while exclusion criteria included patients with conditions that could affect drug metabolism or response to therapy. The main variables to be assessed in this study were length of stay, which is one of the key indicators of anticoagulant effectiveness. In addition, this study also compared the cost-effectiveness of hospital care. This data will be collected through electronic medical records, followed by rigorous statistical analysis. Independent t-test and chi-square by which quantitative data, while multivariate analysis was applied to control potential confounding variables. Two anticoagulant groups were used as samples containing fondaparinux and bovine enoxaparin, respectively. Based on the observational results showed that the average length of stay for patients using the group fondaparinux was shorter than bovine enoxaparin. The bovine enoxaparin group has a lower price per dose, but based on the LOS, the fondaparinux group can reduce total hospital costs, because it has a shorter length of stay. The expectation of this research will provide insight into the effectiveness of halal anti-coagulant drugs in muslim patients, which will also assist in clinical decision making. Hopefully, the results of this research will be useful in Indonesia and other countries with large muslim populations, and can provide the scientific confirmation needed to validate the use of halal medicines. Keywords: Anticoagulant, Effectiveness, Enoxaparin, Fondaparinux, Halal pharmaceuticals.